Glucocorticoid excess and COVID-19 disease

The pandemic of coronavirus disease (COVID-19), a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is causing high and rapid morbidity and mortality. Immune system response plays a crucial role in controlling and resolving the viral infection. Exogenous or endogenous g...

Full description

Saved in:
Bibliographic Details
Published in:Reviews in endocrine & metabolic disorders 2021-12, Vol.22 (4), p.703-714
Main Authors: Guarnotta, Valentina, Ferrigno, Rosario, Martino, Marianna, Barbot, Mattia, Isidori, Andrea M., Scaroni, Carla, Ferrante, Angelo, Arnaldi, Giorgio, Pivonello, Rosario, Giordano, Carla
Format: Article
Language:English
Subjects:
Coronaviruses
COVID-19
Cushing syndrome
Cushing Syndrome - epidemiology
Cushing Syndrome - etiology
Diabetes
Diabetes mellitus
Endocrinology
Glucocorticoids
Humans
Immune system
Infections
Internal Medicine
Medicine
Medicine & Public Health
Morbidity
Pandemics
Patients
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Thromboembolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The pandemic of coronavirus disease (COVID-19), a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is causing high and rapid morbidity and mortality. Immune system response plays a crucial role in controlling and resolving the viral infection. Exogenous or endogenous glucocorticoid excess is characterized by increased susceptibility to infections, due to impairment of the innate and adaptive immune system. In addition, diabetes, hypertension, obesity and thromboembolism are conditions overrepresented in patients with hypercortisolism. Thus patients with chronic glucocorticoid (GC) excess may be at high risk of developing COVID-19 infection with a severe clinical course. Care and control of all comorbidities should be one of the primary goals in patients with hypercortisolism requiring immediate and aggressive treatment. The European Society of Endocrinology (ESE), has recently commissioned an urgent clinical guidance document on management of Cushing’s syndrome in a COVID-19 period. In this review, we aim to discuss and expand some clinical points related to GC excess that may have an impact on COVID-19 infection, in terms of both contagion risk and clinical outcome. This document is addressed to all specialists who approach patients with endogenous or exogenous GC excess and COVID-19 infection.
ISSN:1389-9155
1573-2606
DOI:10.1007/s11154-020-09598-x